Regeneron Pharmaceuticals (REGN) Gains from Investment Securities (2010 - 2026)

Regeneron Pharmaceuticals' Gains from Investment Securities history runs 17 years deep, the most recent figure standing at $73.2 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 2387.5% year-over-year to $73.2 million; the TTM figure through Mar 2026 stood at $608.5 million (down 40.69% YoY), while the FY2025 annual figure was $532.1 million, down 48.29% from the prior year.
• Gains from Investment Securities was $73.2 million for Q1 2026 at Regeneron Pharmaceuticals, down from $519.2 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $772.8 million in Q3 2024 to a low of -$237.1 million in Q2 2022.
• Historically, Gains from Investment Securities has averaged $74.5 million across 5 years, with a median of $3.0 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Gains from Investment Securities tumbled 3100.0% in 2025, then jumped 2387.5% in 2026.
• A 5-year view of Gains from Investment Securities shows it stood at -$169.0 million in 2022, then soared by 110.36% to $17.5 million in 2023, then jumped by 1348.0% to $253.4 million in 2024, then jumped by 104.89% to $519.2 million in 2025, then plunged by 85.9% to $73.2 million in 2026.
• The last three Gains from Investment Securities figures came in at $73.2 million (Q1 2026), $519.2 million (Q4 2025), and -$4.8 million (Q3 2025), per Business Quant data.